1. Scrip
  2. >>Business

VC Roundup: More Funds Raise Cash For Biotech; Morphic Closes $51.5m Series A

 
• By Mandy Jackson

Five venture capital firms raised new funds to finance biopharma companies in June and five therapeutics developers closed early-stage funding rounds during the last week of June.

DNA

June saw five venture capital firms close new funds to back health care and life science companies, and Kleiner Perkins Caufield & Byers (KPCB) – one of the most prolific VC firms so far this year – disclosed in a June 29 US Securities and Exchange Commission (SEC) filing that it is raising at least $400m for its 17th fund.

Five of the top 10 most active venture capital investors in the US during the first half of 2016 are firms with biopharmaceutical companies in their portfolios. KPCB tied with Khosla Ventures – another occasional therapeutics investor – at no. 2 with 30 investments each, according to the investment data tracking firm PitchBook

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

Which Firms Are Most Exposed To Prasad’s Possible Accelerated Approvals Clampdown?

 
• By Andrew McConaghie

Vaccine and accelerated approvals are expected to face greater scrutiny under new CBER leader Vinay Prasad, but he has promised “no light switch change” to policy, giving some reassurance to companies whose share prices have been battered.

Building Up US Biopharma Manufacturing Will Require Investments In Talent

 
• By Jessica Merrill

Workforce development will be essential to meeting president Trump’s goal to return biopharma manufacturing to the US.

Finance Watch: Deerfield Closes $600m-Plus VC Fund; Gates Speeds Up Health Investments

 
• By Mandy Jackson

Private Company Edition: Deerfield’s third innovations fund will back therapeutics and other opportunities, the Gates Foundation – a sometimes funder of biotech firms – will spend $200bn over the next 20 years, and NewLimit raised a $130m series B round, among other financings.

Pharma Left Hanging After US/UK Trade Pact

 
• By Kevin Grogan

An ‘historic economic prosperity deal’ does not include the sector.

More from Scrip

Pharma Left Hanging After US/UK Trade Pact

 
• By Kevin Grogan

An ‘historic economic prosperity deal’ does not include the sector.

Chinese Vaccine Makers Turn To Emerging Markets

 
• By Dexter Jie Yan

Chinese producers of novel vaccines are increasingly pivoting to developing markets overseas in the face of a collapse in their domestic sales.

Viatris Will File ‘Fast-Acting’ Meloxicam For FDA Approval This Year

 
• By Joseph Haas

Seven years after acquiring it, Viatris will seek approval of a meloxicam formulation for acute pain backed by data from two Phase III studies in post-surgical pain settings.